 SAN DIEGO, May 5, 2021 PRNewswire -- Neurocrine Biosciences, Inc. Nasdaq: NBIX today announced its financial results for the first quarter ended March 31, 2021 and provided revised full-year 2021 financial expense guidance. Our first quarter results reflect a lower than normal refill rate per patient due to the typical seasonal payor dynamics for INGREZZA that were exacerbated by COVID. 